Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy

Small cell lung cancer cells (SCLC) are differentially sensitive to inhibitors of the BCL-2 family. Here the authors analyse the response to BH3 mimetics in SCLC, delineate patterns of expression of apoptotic proteins correlated with differential sensitivities and demonstrate a synergistic anti-tumo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Akane Inoue-Yamauchi, Paul S. Jeng, Kwanghee Kim, Hui-Chen Chen, Song Han, Yogesh Tengarai Ganesan, Kota Ishizawa, Sylvia Jebiwott, Yiyu Dong, Maria C. Pietanza, Matthew D. Hellmann, Mark G. Kris, James J. Hsieh, Emily H. Cheng
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/a5d834b769b2400b86f4baf0dda324e5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a5d834b769b2400b86f4baf0dda324e5
record_format	dspace
spelling	oai:doaj.org-article:a5d834b769b2400b86f4baf0dda324e52021-12-02T17:06:05ZTargeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy10.1038/ncomms160782041-1723https://doaj.org/article/a5d834b769b2400b86f4baf0dda324e52017-07-01T00:00:00Zhttps://doi.org/10.1038/ncomms16078https://doaj.org/toc/2041-1723Small cell lung cancer cells (SCLC) are differentially sensitive to inhibitors of the BCL-2 family. Here the authors analyse the response to BH3 mimetics in SCLC, delineate patterns of expression of apoptotic proteins correlated with differential sensitivities and demonstrate a synergistic anti-tumour activity between ABT-199 and anthracyclines or CDK9 inhibitors.Akane Inoue-YamauchiPaul S. JengKwanghee KimHui-Chen ChenSong HanYogesh Tengarai GanesanKota IshizawaSylvia JebiwottYiyu DongMaria C. PietanzaMatthew D. HellmannMark G. KrisJames J. HsiehEmily H. ChengNature PortfolioarticleScienceQENNature Communications, Vol 8, Iss 1, Pp 1-14 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Akane Inoue-Yamauchi Paul S. Jeng Kwanghee Kim Hui-Chen Chen Song Han Yogesh Tengarai Ganesan Kota Ishizawa Sylvia Jebiwott Yiyu Dong Maria C. Pietanza Matthew D. Hellmann Mark G. Kris James J. Hsieh Emily H. Cheng Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
description	Small cell lung cancer cells (SCLC) are differentially sensitive to inhibitors of the BCL-2 family. Here the authors analyse the response to BH3 mimetics in SCLC, delineate patterns of expression of apoptotic proteins correlated with differential sensitivities and demonstrate a synergistic anti-tumour activity between ABT-199 and anthracyclines or CDK9 inhibitors.
format	article
author	Akane Inoue-Yamauchi Paul S. Jeng Kwanghee Kim Hui-Chen Chen Song Han Yogesh Tengarai Ganesan Kota Ishizawa Sylvia Jebiwott Yiyu Dong Maria C. Pietanza Matthew D. Hellmann Mark G. Kris James J. Hsieh Emily H. Cheng
author_facet	Akane Inoue-Yamauchi Paul S. Jeng Kwanghee Kim Hui-Chen Chen Song Han Yogesh Tengarai Ganesan Kota Ishizawa Sylvia Jebiwott Yiyu Dong Maria C. Pietanza Matthew D. Hellmann Mark G. Kris James J. Hsieh Emily H. Cheng
author_sort	Akane Inoue-Yamauchi
title	Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
title_short	Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
title_full	Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
title_fullStr	Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
title_full_unstemmed	Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
title_sort	targeting the differential addiction to anti-apoptotic bcl-2 family for cancer therapy
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/a5d834b769b2400b86f4baf0dda324e5
work_keys_str_mv	AT akaneinoueyamauchi targetingthedifferentialaddictiontoantiapoptoticbcl2familyforcancertherapy AT paulsjeng targetingthedifferentialaddictiontoantiapoptoticbcl2familyforcancertherapy AT kwangheekim targetingthedifferentialaddictiontoantiapoptoticbcl2familyforcancertherapy AT huichenchen targetingthedifferentialaddictiontoantiapoptoticbcl2familyforcancertherapy AT songhan targetingthedifferentialaddictiontoantiapoptoticbcl2familyforcancertherapy AT yogeshtengaraiganesan targetingthedifferentialaddictiontoantiapoptoticbcl2familyforcancertherapy AT kotaishizawa targetingthedifferentialaddictiontoantiapoptoticbcl2familyforcancertherapy AT sylviajebiwott targetingthedifferentialaddictiontoantiapoptoticbcl2familyforcancertherapy AT yiyudong targetingthedifferentialaddictiontoantiapoptoticbcl2familyforcancertherapy AT mariacpietanza targetingthedifferentialaddictiontoantiapoptoticbcl2familyforcancertherapy AT matthewdhellmann targetingthedifferentialaddictiontoantiapoptoticbcl2familyforcancertherapy AT markgkris targetingthedifferentialaddictiontoantiapoptoticbcl2familyforcancertherapy AT jamesjhsieh targetingthedifferentialaddictiontoantiapoptoticbcl2familyforcancertherapy AT emilyhcheng targetingthedifferentialaddictiontoantiapoptoticbcl2familyforcancertherapy
_version_	1718381748937555968

Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy

Ejemplares similares